Company Analysis - Sanofi has entered a global licensing agreement with Pfizer for the PD-1/VEGF dual antibody 707, which includes an upfront payment of $1.25 billion, potential milestone payments of up to $4.8 billion, and a double-digit sales revenue share [2] - Pfizer will subscribe to 31,142,500 shares of Sanofi at HKD 25.2 per share, totaling approximately HKD 785 million (around $100 million) [2] - The agreement grants Pfizer an option for rights in China, which could yield an additional $150 million if exercised [2] Clinical Development Insights - The 707 antibody is noted for its differentiated structure, which may provide advantages in efficacy and safety compared to similar PD-1/VEGF dual antibodies [5] - Pfizer's management expressed confidence in the clinical data for 707, indicating its potential as a foundational treatment option for multiple indications [5][6] - The Phase II clinical data presented at ASCO showed a 64.7% confirmed overall response rate (cORR) in patients with PD-L1+ NSCLC [5] Market Outlook - Pfizer plans to accelerate the global Phase III clinical development of 707, exploring its use as a monotherapy and in combination with chemotherapy and ADCs [6] - The report maintains a "Buy" rating for Sanofi with a target price of HKD 37.67, reflecting an upward adjustment in sales expectations due to Pfizer's rapid development plans [6] Other Company Insights - Thermo Fisher Scientific reported a 3.0% year-over-year revenue growth in Q2 2025, with adjusted EPS declining by 0.2% [7] - The company has raised its full-year guidance, expecting revenue growth between 1.7% and 3.1% [7][8] - Zhejiang Dingli's Q2 2025 net profit increased by 19% year-over-year, primarily driven by foreign exchange gains [8]